Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNutriband Inc. Warrant

Nutriband Inc. Warrant

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-12T15:47:14.505351Z
Market Cap
0.00M

Momentum Score

…

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.19
Low
2.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
2.09M
Revenue Per Share
0.26
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-73.08%
Net Debt
-0.25M
ROCE
-63.64%
Diluted EPS TTM
-0.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax -4.48M -6.18M -2.93M -2.72M -3.33M
Net income -4.81M -8.42M -3.21M -2.80M -3.33M
Selling general administrative 3.92M 4.02M 4.02M 1.79M 3.29M
Gross profit 0.75M 0.50M 0.36M -0.18M -0.04M
Reconciled depreciation 0.37M 0.32M 0.17M 0.09M 0.04M
Ebit -4.15M -3.93M -2.60M -1.97M -3.33M
Ebitda -3.78M -3.61M -2.50M -1.88M -3.29M
Depreciation and amortization 0.37M 0.32M 0.10M 0.09M 0.04M
Operating income -4.15M -3.93M -2.60M -1.97M -3.33M
Other operating expenses 6.23M 5.35M 3.54M 2.34M 3.58M
Interest expense 0.01M 0.12M 0.28M 0.07M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.01M -0.12M -0.35M -0.07M -
Income tax expense 0.33M 2.25M 0.28M 0.07M -
Total revenue 2.08M 1.42M 0.94M 0.37M 0.25M
Total operating expenses 4.90M 4.43M 2.96M 1.79M 3.29M
Cost of revenue 1.33M 0.92M 0.58M 0.55M 0.29M
Total other income expense net -0.34M -2.25M -0.34M -0.75M -
Net income from continuing ops -4.48M -6.18M -2.93M -2.72M -3.33M
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 7.52M 9.46M 12.74M 9.93M 2.20M
Intangible assets 0.67M 0.78M 0.93M 1.01M 0.31M
Other current assets 0.21M 0.37M 0.37M 0.37M 0.02M
Total liab 1.08M 0.88M 0.88M 2.82M 2.02M
Total stockholder equity 6.44M 8.57M 11.86M 7.11M 0.18M
Other current liab 0.68M 0.53M 0.64M 0.94M 0.93M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -27.98M -22.49M -18.01M -11.84M -8.90M
Good will 5.02M 5.02M 5.35M 7.53M 1.72M
Cash 0.49M 1.99M 4.89M 0.15M 0.01M
Total current liabilities 1.00M 0.75M 0.78M 2.57M 2.02M
Current deferred revenue 0.16M 0.16M 0.11M 0.09M -
Net debt -0.25M -1.80M -4.76M 1.64M 0.31M
Short term debt 0.16M 0.05M 0.03M 1.54M 0.32M
Short long term debt 0.13M 0.02M 0.01M 1.52M 0.31M
Short long term debt total 0.24M 0.19M 0.13M 1.79M 0.32M
Other stockholder equity 34.41M 31.06M 29.86M 18.94M 9.07M
Total current assets 1.02M 2.69M 5.47M 0.31M 0.04M
Net receivables 0.15M 0.11M 0.07M 0.11M 0.01M
Long term debt 0.08M 0.10M 0.10M 0.15M -
Inventory 0.17M 0.23M 0.13M 0.05M -
Accounts payable 0.68M - 0.64M - 0.77M
Accumulated other comprehensive income -0.00M -0.00M -0.00M -0.00M -0.00M
Non current assets total 6.50M 6.76M 7.27M 9.61M 2.15M
Capital lease obligations 0.03M 0.07M 0.02M 0.12M 0.01M
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -0.08M -0.08M 0.07M 0.00M -0.40M
Total cash from financing activities 0.16M 7.63M 0.37M 0.43M 1.98M
Net income -4.48M -6.18M -2.93M -2.72M -3.33M
Change in cash -2.91M 4.74M 0.14M -0.46M 0.47M
Begin period cash flow 4.89M 0.15M 0.01M 0.47M 0.09M
End period cash flow 1.99M 4.89M 0.15M 0.01M 0.47M
Total cash from operating activities -2.99M -2.81M -0.30M -0.89M -1.11M
Issuance of capital stock 0.00M 6.42M 0.52M 0.00M 1.50M
Depreciation 0.37M 0.32M 0.17M 0.09M 0.04M
Dividends paid - -0.20M - - -
Change to inventory -0.10M -0.08M -0.01M 0.00M 0.00M
Change to account receivables -0.04M 0.04M -0.09M 0.00M -0.01M
Sale purchase of stock -0.12M -0.10M -0.10M - -
Other cashflows from financing activities 0.30M 3.14M 0.21M 0.43M 0.53M
Capital expenditures 0.08M 0.08M 0.08M 0.00M 0.00M
Change in working capital -0.22M -0.54M 0.11M 0.71M 0.40M
Stock based compensation 0.73M 1.36M 2.00M 0.25M 1.76M
Other non cash items 0.61M 2.23M 0.36M 0.09M 0.02M
Free cash flow -3.07M -2.89M -0.30M -0.89M -1.11M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Nutriband Inc. Warrant

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

121 South Orange Avenue, Orlando, FL, United States, 32801

407 377 6695

https://nutriband.com

Name Title Year Born
Mr. Serguei Melnik Founder, President, Company Secretary & Executive Chairman of the Board 1974
Mr. Gareth Sheridan Founder, CEO & Director 1990
Mr. Gerald Goodman CFO & Chief Accounting Officer 1948
Dr. Alan Smith Ph.D. COO & President of 4P Therapeutics 1966
Mr. Patrick Ryan Chief Technical Officer 1986
Dr. Jeffrey Patrick Pharm.D. Chief Scientific Officer 1970
Mr. Tyler Overk President of Active Intelligence 1984

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…